Cargando…

Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report

RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Saviola, Gianantonio, Abdi-Ali, Lul, Sacco, Silvano, Comini, Laura, Plewnia, Katrin, Rossi, Maja, Orrico, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310541/
https://www.ncbi.nlm.nih.gov/pubmed/30544400
http://dx.doi.org/10.1097/MD.0000000000013350
_version_ 1783383456373276672
author Saviola, Gianantonio
Abdi-Ali, Lul
Sacco, Silvano
Comini, Laura
Plewnia, Katrin
Rossi, Maja
Orrico, Alfredo
author_facet Saviola, Gianantonio
Abdi-Ali, Lul
Sacco, Silvano
Comini, Laura
Plewnia, Katrin
Rossi, Maja
Orrico, Alfredo
author_sort Saviola, Gianantonio
collection PubMed
description RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. PATIENT CONCERNS: Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. DIAGNOSIS AND INTERVENTIONS: Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). OUTCOMES: The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. LESSONS: Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity.
format Online
Article
Text
id pubmed-6310541
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63105412019-01-14 Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report Saviola, Gianantonio Abdi-Ali, Lul Sacco, Silvano Comini, Laura Plewnia, Katrin Rossi, Maja Orrico, Alfredo Medicine (Baltimore) Research Article RATIONALE: The mechanisms of action of MTX (methotrexate) in the treatment of RA (rheumatoid arthritis) and PsA (psoriatic arthritis) is related to its antifolic activity, due to the high affinity for enzymes that require folate cofactors as dihydrofolate reductase and to the anti-inflammatory activity derivated from the inhibition of thymidylate synthetase that leads to the over-production of adenosine. PATIENT CONCERNS: Our patient was a 41-year-old female, affected by PsA in treatment since 2 years with low-dose methylprednisolone and low-dose subcutaneous MTX. The treatment was effective. The patient subacutely developed a severe paraparesis with impossibility of gait or standing without aid and was admitted to a Neurology Department where the cause of the paraparesis was not clear in spite of accurate radiological neurophysiologic and laboratory tests. Therefore, she was admitted in a rehabilitation unit. DIAGNOSIS AND INTERVENTIONS: Paraparesis in PsA patient in treatment with methotrexate. MTX toxicity was hypothesized; therefore the drug was discontinued while i.m. folic acid and cyanocobalamin were administered for 20 days. The diagnosis was clinical, based on neurological examination (paraparesis) and on the chronic use of MTX (hypothesis of toxicity). OUTCOMES: The patient obtained a complete resolution of paraparesis. Genetic analyses showed associated a compound heterozygosity for the c.1298A>C and c.677C>T variants of methylenetetrahydrofolate reductase (MTHFR) gene. LESSONS: Neurological side effects of MTX are uncommon. In literature no previous case of MTX induced paraparesis in patients treated with low-dose MTX for chronic arthritis has been described. The association between the gene polymorphisms of MTHFR (c.1298A>C and c.677C>T) and MTX toxicity in arthritis patients is confirmed. The case also confirms that folates are a precious antidote of MTX toxicity. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310541/ /pubmed/30544400 http://dx.doi.org/10.1097/MD.0000000000013350 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Saviola, Gianantonio
Abdi-Ali, Lul
Sacco, Silvano
Comini, Laura
Plewnia, Katrin
Rossi, Maja
Orrico, Alfredo
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title_full Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title_fullStr Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title_full_unstemmed Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title_short Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report
title_sort complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298a>c and c.677c>t mthfr polymorphism: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310541/
https://www.ncbi.nlm.nih.gov/pubmed/30544400
http://dx.doi.org/10.1097/MD.0000000000013350
work_keys_str_mv AT saviolagianantonio completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT abdialilul completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT saccosilvano completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT cominilaura completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT plewniakatrin completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT rossimaja completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport
AT orricoalfredo completeclinicalandfunctionalrecoveryfollowinglowdosemethotrexaterelatedparaparesisinapatientwithcompoundc1298acandc677ctmthfrpolymorphismacasereport